



ICON Selected by Roche for Technology Partnership

Roche First to Implement MIRA™ as an Online Medical Image Repository

DUBLIN--(BUSINESS WIRE)-- **ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209)**, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by Roche as its technology partner for storing and managing medical images collected during the company's clinical research programs.

Roche is using ICON's MIRA™ (Medical Image Review and Analysis) software as the company's central repository for medical images. MIRA is the core application used by ICON Medical Imaging in its daily operations and provides functionality for imaging and clinical data management, image analysis, project management and document management. MIRA™ is being implemented by Roche in a Software as a Service (SaaS) model, which provides Roche with 24/7 access to imaging data from anywhere in the world and also eliminates the technology costs associated with purchasing and maintaining an image management system in-house. ICON is the first medical imaging provider to offer clients a SaaS solution for their image management needs.

Commenting on the partnership, Dr. Gudrun Zahlman, Leader Imaging Infrastructure at Roche, commented, "We committed to ICON and MIRA after a one year pilot program. The comprehensive functionality of MIRA, the US and EU redundancy of the data, and the responsive nature of the ICON staff, proved the best fit for Roche's needs. Additionally, we have achieved the seamless integration of images hosted in MIRA with Roche's clinical data repository and data mining tools for trial decision making, and have integrated 3rd party image analysis software within MIRA for quantitative biomarker research."

"We are delighted to have been selected as a technology partner by the Roche informatics team and to be involved with such a collaborative and forward-thinking group," commented Andrew Kraus, Executive Vice President and CTO at ICON Medical Imaging. "MIRA's superior imaging capabilities, and fault tolerance mechanisms, made it an ideal solution to offer clients in a SaaS framework. MIRA's extensible architecture also enables plug-in modules for advanced analysis. Today's announcement is another good example of the innovation that ICON is bringing to the drug development process and we look forward to building on our close technology partnership with Roche."

About ICON plc

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has around 8,600 employees, operating from 84 locations in 40 countries.

Further information is available at www.iconplc.com

DISCLOSURE NOTICE: This release contains, and our officers and representatives may from time to time make, "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "strategy" and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, strategic actions, including our success in integrating PriceSpective; general economic and financial conditions; the extent to which we are successful in implementing our strategy, gaining new, long-term relationships with customers and retaining existing ones; the risk of competition on our industry; developments and changes in laws and regulations; and such other factors as discussed in Part I, Item 3 "Risk Factors" in our Form 20-F for the fiscal year ended December 31, 2010. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

ICON/ICLR-G

ICON Investor Contacts

Investor Relations

1-888-381-7923

or

Sam Farthing, VP Investor Relations

+ 353 —1-291-2251

or

ICON Media Contacts

Rosie Allan /Genevieve Tuck

at Weber Shandwick

Tel: +44-020-7067-0000

Source: ICON plc

News Provided by Acquire Media